Solifenacin

Category: pharmacological

Aliases: VESIcare

Pharmacological Mechanism

Competitive muscarinic receptor antagonist (M3-preferring) for overactive bladder — reduces detrusor overactivity. Hepatic CYP3A4 metabolism.

Half-Life (t½)

PO: 55h

Dosing Guidelines

• PO: Typical 5 mg (Range: 5–10 mg)

Target Organ Systems

• nervous

Notes

PK from FDA prescribing information (DailyMed setid 1d8e8f6f-0a59-479f-8415-c5c5f19e1977): absolute bioavailability ~90% (F 0.9), steady-state Vd ~600 L, terminal t½ ~45–68 h, Tmax 3–8 h, CYP3A4. ka_hr 0.85 derived from Tmax ~5 h (ke from t½ 55 h).

Chemical Identifiers

• PubChem CID: 154059
• Formula: C23H26N2O2
• Molecular weight: 362.5 g/mol
• InChIKey: FBOUYBDGKBSUES-VXKWHMMOSA-N
• SMILES: C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5

References

• PMID 12122494